Screener
Aquestive Therapeutics, Inc. AQST Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s accounts payable?
- Aquestive Therapeutics, Inc. (AQST) reported accounts payable of $8.97M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s accounts payable changed year-over-year?
- Aquestive Therapeutics, Inc.'s accounts payable decreased by 25.0% year-over-year, from $11.95M to $8.97M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s accounts payable has grown at a 33.3% compound annual growth rate (CAGR), from $7.09M to $29.86M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Aquestive Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude